The move implies that EMA has confirmed the completion of the application and will begin the review procedure.
Tofacitinib has been studied in the Phase 3 ORAL (Oral Rheumatoid Arthritis Phase 3 TriaLs) program for the treatment of moderate-to-severe active RA.
The drug candidate is also being assessed in two ongoing long-term open-label extension studies.